The journal of mental health administration

, Volume 17, Issue 2, pp 138–144 | Cite as

Myths and mystifications of managed care

  • John P. Docherty
Article

Abstract

This paper reviews some of the major conceptual “myths” that have been propagated to support the cost containment activity referred to as “managed care”. It discusses the facts and logic inherent in these myths and examines the implications such myths have for compromising the integrity of clinical care.

Keywords

Therapeutic Alliance Pimozide Borderline Personality Disorder Chemical Dependency Employer Sponsor Health 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Employer Sponsored Health Insurance in America: preliminary results from 1988 survey. Medical Benefits 1989; 6(2):6–7.Google Scholar
  2. 2.
    Janowsky DA, Davis JM: Methylphenidate, dextroamphetamine, and levamphetamine. Archives of General Psychiatry 1976; 33:304–308.PubMedGoogle Scholar
  3. 3.
    Van Kammen DP, Docherty JP, Bunney WE: Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biological Psychiatry 1982; 17(2):233–242.PubMedGoogle Scholar
  4. 4.
    McGalashan TH: Schizophrenia: psychosocial treatments and the role of psychosocial factors in its etiology and pathogenesis. In: Hales RE, Frances AJ (eds): Psychiatry Update: American Psychiatric Association Annual Review. Vol 5, Washington, D.C.: American Psychiatric Press, 1986, pp.96–111.Google Scholar
  5. 5.
    Quitkin FM, Rabkin JG, Ross D: Duration of antidepressant drug treatment: What is an adequate trial? Archives of General Psychiatry 1984; 41:238–245.PubMedGoogle Scholar
  6. 6.
    Meltzer HY: Duration of a Closapine trial in neuroleptic-resistant schizophrenia. Archives of General Psychiatry 1989; 46:672.PubMedGoogle Scholar
  7. 7.
    Herman JL, Perry JC, Vanderkolk BA: Childhood trauma in borderline personality disorder. American Journal of Psychiatry 1989; 146:490–495.PubMedGoogle Scholar
  8. 8.
    Frank A, Gunderson J: The role of the therapeutic alliance in the treatment of schizophrenia: relationship to course and outcome. Archives of General Psychiatry 1990; 47:228–236.PubMedGoogle Scholar
  9. 9.
    Docherty JP, Fiester SJ: The therapeutic alliance and compliance with psychopharmacology. In: Hales RE, Frances AJ (eds): Psychiatry Update: American Psychiatric Association Annual Review. Vol 4, Washington, DC: American Psychiatric Press, 1985, pp. 607–632.Google Scholar
  10. 10.
    Docherty JP: The therapeutic alliance and treatment outcome: introduction to section V. In: Hales RE, Frances AJ (eds): Psychiatry Update: American Psychiatric Association Annual Review. Vol 4, Washington, DC: American Psychiatric Press, 1985, pp. 527–531.Google Scholar
  11. 11.
    Hughes vs. Blue Cross of Northern California: 245 Cal Rptr. 273 (Cal. Appl. 1 Dist.), 1988.Google Scholar

Copyright information

© Association of Mental Health Administrators 1990

Authors and Affiliations

  • John P. Docherty
    • 1
    • 2
  1. 1.Brookside HospitalNashua
  2. 2.Tufts UniversityUSA

Personalised recommendations